NZ321546A - Treatment of traumatic brain injury using 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine - Google Patents

Treatment of traumatic brain injury using 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine

Info

Publication number
NZ321546A
NZ321546A NZ321546A NZ32154696A NZ321546A NZ 321546 A NZ321546 A NZ 321546A NZ 321546 A NZ321546 A NZ 321546A NZ 32154696 A NZ32154696 A NZ 32154696A NZ 321546 A NZ321546 A NZ 321546A
Authority
NZ
New Zealand
Prior art keywords
traumatic brain
brain injury
methylpyridine
tetrazol
tetrahydro
Prior art date
Application number
NZ321546A
Inventor
Brian R Pike
Original Assignee
H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H filed Critical H
Publication of NZ321546A publication Critical patent/NZ321546A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The compound 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine of formula (I) improves cognitive performance and attenuates injury-reduced reductions of cholinergic neurones in traumatic brain injury models and is useful for the manufacture of a pharmaceutical preparation for the treatment of traumatic brain injury.
NZ321546A 1995-11-06 1996-11-05 Treatment of traumatic brain injury using 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine NZ321546A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (1)

Publication Number Publication Date
NZ321546A true NZ321546A (en) 2000-12-22

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ321546A NZ321546A (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury using 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine

Country Status (18)

Country Link
EP (1) EP0866706A1 (en)
JP (1) JPH11514654A (en)
KR (1) KR19990067353A (en)
AU (1) AU706594B2 (en)
BG (1) BG63150B1 (en)
BR (1) BR9611396A (en)
CA (1) CA2234824A1 (en)
CZ (1) CZ287441B6 (en)
EA (1) EA000531B1 (en)
HU (1) HUP9901051A2 (en)
IS (1) IS4726A (en)
NO (1) NO982036L (en)
NZ (1) NZ321546A (en)
PL (1) PL326490A1 (en)
SK (1) SK58198A3 (en)
TR (1) TR199800801T2 (en)
WO (1) WO1997017074A1 (en)
ZA (1) ZA969320B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (en) * 1997-07-01 2000-12-13 Lundbeck & Co As H SALE OF ADDITION OF MALEIC ACID OF 5- (2-ETIL-2-H-TETRAZOL-5-IL) -1-METHYL-1,2,3,6-TETRAHIDROPIRIDINA, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT, ITS USE IN THERAPY AND METHOD OF PREPARATION OF THE SAME.
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
CA2234824A1 (en) 1997-05-15
ZA969320B (en) 1997-05-30
JPH11514654A (en) 1999-12-14
EA000531B1 (en) 1999-10-28
PL326490A1 (en) 1998-09-28
BR9611396A (en) 1999-07-13
EP0866706A1 (en) 1998-09-30
EA199800434A1 (en) 1998-10-29
AU706594B2 (en) 1999-06-17
CZ138998A3 (en) 1998-10-14
HUP9901051A2 (en) 2000-03-28
SK58198A3 (en) 1998-10-07
NO982036D0 (en) 1998-05-05
WO1997017074A1 (en) 1997-05-15
MX9803432A (en) 1998-09-30
TR199800801T2 (en) 1998-08-21
NO982036L (en) 1998-06-25
IS4726A (en) 1998-04-27
CZ287441B6 (en) 2000-11-15
BG63150B1 (en) 2001-05-31
AU7490096A (en) 1997-05-29
KR19990067353A (en) 1999-08-16
BG102480A (en) 1999-01-29

Similar Documents

Publication Publication Date Title
TW224942B (en)
IL116203A (en) Pharmaceutical compositions for the treatment of emesis comprising (2s, 3s) -3-(2-methoxybenzylamino)-2-phenylpiperidine and ondansetron
AU8392291A (en) Tachykinin agonists for treatment of alzheimer's disease
AU1808488A (en) Compounds for the treatment of alzheimer's disease
CA2264097A1 (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
IL132107A0 (en) Substituted phenyl derivatives their preparation and use
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
AU4048295A (en) Peptide medicaments for the treatment of disease
AU4524889A (en) Method for the treatment of periodontal disease
NZ321546A (en) Treatment of traumatic brain injury using 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine
AU5801996A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
AU4759390A (en) Method of medical treatment of alzheimer's disease
AU4464089A (en) Compositions and methods for the treatment of skin disease containing mevinolin or synvinolin or related compounds
CA2235747A1 (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
AU4517893A (en) An oral formulation for gastric antibacterial treatment as well as a process thereof and the use
AU9173191A (en) Medicaments for the treatment of papillomavirus diseases
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
WO1996031208A3 (en) Use of substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders
AU8268491A (en) Phosphonopyrrolidine- and piperidine-containing pseudopeptides of the statin type, a process for their preparation and their use as medicaments against retroviruses
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
AU7718796A (en) 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus
AU8096094A (en) Use of nicotine substitutes for the treatment of nicotine withdrawal
AU7719491A (en) Therapeutic compound
AU3881889A (en) Human interferon-gamma, process to prepare said human interferon-gamma, and its use
AU7209394A (en) Gallium complexes for the treatment of free radical-induced diseases